Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

Also called NCT01320397

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
RostaQuo S.p.A. (from the registry)
Registry
  • NCT NCT01320397
  • EudraCT 2010-022073-34
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Ireland, Italy, Poland (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01320397. Randomized; quadruple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Antihypertensive Effect of Rostafuroxin Compared With Losartan in Hypertensive Patients Bearing Specified Gene Mutations
Condition
Essential Hypertension
Intervention (Drug)
Rostafuroxin
Intervention (Drug)
Rostafuroxin
Intervention (Drug)
Rostafuroxin
Intervention (Drug)
Losartan
Lead sponsor
RostaQuo S.p.A. (class: industry)

Record details

Record id
cardio:ct-nct01320397
Content hash
edfce3f056eb474f78de92f39ac39917b37093968da5c06831b90ad727001207